Pioglitazone in the treatment of major depression

pioglitazone as adjuvant therapy in the treatment of major depression: a randomised and double blind study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201012031556N20

Enrollment

Registered

2010-12-04

Start date

2010-04-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive episode. Major Depressive episode

Interventions

Intervention 1: Tablet Citalopram 40 mg/day plus Tablet Pioglitazone30 mg/day as intervention group for 6 weeks. Intervention 2: Tablet Citalopram 40 mg/day plusTablet placebo as control group for 6

Treatment - Drugs

Placebo

Tablet Citalopram 40 mg/day plus Tablet Pioglitazone30 mg/day as intervention group for 6 weeks

Tablet Citalopram 40 mg/day plusTablet placebo as control group for 6 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Presence of Major Depressive Disorder based on DSM-IV criteria, Baseline Hamilton Depression Rating Scale (HAM-D) (17-item) score of at least 22. Exclusion criteria: Presence of Psychosis, any other diagnosis in Axis I and II, Receiving psychotropic medications, receiving any antidepressants during past one month or ECT during past two months, Presence of hypothyroidism or cardiovascular problems, pregnancy or nursing women

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of depression. Timepoint: Baseline and weeks 2,4 and 6. Method of measurement: Hamiltion Depression Rating Scale 17-Item.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026